Naphthamide Derivatives Multi-Target Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with abnormal protein kinase and histone deacetylase activities, such as cancer, lack effective and selective inhibitors with low toxicity and high anti-tumor activity, particularly for solid tumors and hematological malignancies.
Innovation Solution
Development of naphthamide derivatives that selectively inhibit protein kinases and histone deacetylases, offering a combination of anti-angiogenesis, anti-proliferation, and immune modulation activities, thereby providing a more effective treatment for solid tumors while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional protein kinase inhibitors are used, then protein kinase activity is inhibited, but selectivity and anti-tumor activity are insufficient with high toxicity
Solution Approach 1:
The patent applies multi-functionality by designing naphthamide derivatives that simultaneously inhibit multiple protein kinases (including EGFR, VEGFR, PDGFR, FGFR) and histone deacetylases, enabling a single compound to address multiple disease mechanisms and improve anti-tumor activity while maintaining selectivity
Solution Approach 2:
The patent employs parameter changes by systematically modifying the chemical structure of naphthamide derivatives through varying substituents at different positions (R1-R6 groups), optimizing pharmacological properties to achieve enhanced selectivity and reduced toxicity while maintaining broad kinase inhibition
2Reliability
If multi-target inhibitors are developed, then anti-tumor activity is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor into distinct functional modules: a core naphthamide scaffold providing HDAC inhibition, and various substituent groups (R1-R6) that can be independently optimized for specific kinase targets, allowing systematic design of multi-target inhibitors with controlled complexity
Solution Approach 2:
The patent uses multi-functionality where the naphthamide core structure serves multiple purposes: inhibiting HDAC enzymes, binding to multiple protein kinase families, and enabling selective pharmacological activity through substituent variation, thereby achieving high anti-tumor activity without proportionally increasing structural complexity
Data Source
AI summary
Isolated compounds of formula I:and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and/or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases, cancer, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic disease, allergies and asthma and/or hormone-related diseases.